Соединенные Штаты - английский - NLM (National Library of Medicine)

akorn - ciclopirox (unii: 19w019zdrj) (ciclopirox - unii:19w019zdrj) - ciclopirox 71.3 mg in 1 ml - (to understand fully the indication for this product, please read the entire indications and usage section of the labeling.) ciclopirox topical solution, 8% (nail lacquer) as a component of a comprehensive management program, is indicated as topical treatment in immunocompetent patients with mild to moderate onychomycosis of fingernails and toenails without lunula involvement, due to tricho-phyto rubrum . the comprehensive management program includes removal of the unattached, infected nails as frequently as monthly, by a health care professional who has special competence in the diagnosis and treatment of nail disorders, including minor nail procedures. the results of use of ciclopirox topical solution, 8% (nail lacquer) in treatment of onychomycosis of the toenail without lunula involvement were obtained from two double-blind, placebo-controlled studies conducted in the us. in these studies, patients with onchomycosis of the great toenails without lunula involvement were treated with ciclopirox topical solu

Соединенные Штаты - английский - NLM (National Library of Medicine)

physicians total care, inc. - ciclopirox (unii: 19w019zdrj) (ciclopirox - unii:19w019zdrj) - ciclopirox 80 mg in 1 ml - (to understand fully the indication for this product, please read the entire indications and usage section of the labeling.) ciclopirox topical solution, 8% (nail lacquer), as a component of a comprehensive management program, is indicated as topical treatment in immunocompetent patients with mild to moderate onychomycosis of fingernails and toenails without lunula involvement, due to trichophyton rubrum . the comprehensive management program includes removal of the unattached, infected nails as frequently as monthly, by a health care professional who has special competence in the diagnosis and treatment of nail disorders, including minor nail procedures. - no studies have been conducted to determine whether ciclopirox might reduce the effectiveness of systemic antifungal agents for onychomycosis. therefore, the concomitant use of 8% ciclopirox topical solution and systemic antifungal agents for onychomycosis, is not recommended. - ciclopirox topical solution, 8% (nail lacquer), should be used onl

Соединенные Штаты - английский - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - ciclopirox (unii: 19w019zdrj) (ciclopirox - unii:19w019zdrj) - ciclopirox 80 mg in 1 ml - (to understand fully the indication for this product, please read the entire indications and usage section of the labeling.) ciclopirox topical solution, 8% as a component of a comprehensive management program, is indicated as topical treatment in immunocompetent patients with mild to moderate onychomycosis of fingernails and toenails without lunula involvement, due to trichophyton rubrum . the comprehensive management program includes removal of the unattached, infected nails as frequently as monthly, by a health care professional who has special competence in the diagnosis and treatment of nail disorders, including minor nail procedures. the results of use of ciclopirox topical solution, 8% in treatment of onychomycosis of the toenail without lunula involvement were obtained from two double-blind, placebo-controlled studies conducted in the united states. in these studies, patients with onychomycosis of the great toenails without lunula involvement were treated with ciclopirox topical solution, 8% in conjun

Соединенные Штаты - английский - NLM (National Library of Medicine)

padagis israel pharmaceuticals ltd - ciclopirox (unii: 19w019zdrj) (ciclopirox - unii:19w019zdrj) - ciclopirox 80 mg in 1 ml - (to understand fully the indication for this product, please read the entire indications and usage section of the labeling.) ciclopirox topical solution, 8% as a component of a comprehensive management program, is indicated as topical treatment in immunocompetent patients with mild to moderate onychomycosis of fingernails and toenails without lunula involvement, due to trichophyton rubrum . the comprehensive management program includes removal of the unattached, infected nails as frequently as monthly, by a health care professional who has special competence in the diagnosis and treatment of nail disorders, including minor nail procedures. the results of use of ciclopirox topical solution, 8% in treatment of onychomycosis of the toenail without lunula involvement were obtained from two double-blind, placebo-controlled studies conducted in the united states. in these studies, patients with onychomycosis of the great toenails without lunula involvement were treated with ciclopirox topical solution, 8% in conjun

Соединенные Штаты - английский - NLM (National Library of Medicine)

cosette pharmaceuticals, inc. - ciclopirox (unii: 19w019zdrj) (ciclopirox - unii:19w019zdrj) - ciclopirox 80 mg in 1 ml - (to understand fully the indication for this product, please read the entire indications and usage section of the labeling.) ciclopirox topical solution, 8%, (nail lacquer), as a component of a comprehensive management program, is indicated as topical treatment in immunocompetent patients with mild to moderate onychomycosis of fingernails and toenails without lunula involvement, due to trichophyton rubrum . the comprehensive management program includes removal of the unattached, infected nails as frequently as monthly, by a health care professional who has special competence in the diagnosis and treatment of nail disorders, including minor nail procedures.      • no studies have been conducted to determine whether ciclopirox might reduce the effectiveness of systemic antifungal agents for onychomycosis. therefore, the concomitant use of 8% ciclopirox topical solution and systemic antifungal agents for onychomycosis, is not recommended.     • ciclopirox topical solution, 8%, (nail lacquer),

Соединенные Штаты - английский - NLM (National Library of Medicine)

rebel distributors corp. - ciclopirox (unii: 19w019zdrj) (ciclopirox - unii:19w019zdrj) - ciclopirox 71.3 mg in 1 ml - (to understand fully the indication for this product, please read the entire indications and usage section of the labeling.) ciclopirox topical solution, 8% (nail lacquer) as a component of a comprehensive management program, is indicated as topical treatment in immunocompetent patients with mild to moderate onychomycosis of fingernails and toenails without lunula involvement, due to tricho-phyto rubrum . the comprehensive management program includes removal of the unattached, infected nails as frequently as monthly, by a health care professional who has special competence in the diagnosis and treatment of nail disorders, including minor nail procedures. - no studies have been conducted to determine whether ciclopirox might reduce the effectiveness of systemic antifungal agents for onychomycosis. therefore, the concomitant use of 8% ciclopirox topical solution and systemic antifungal agents for onychomycosis, is not recommended. - ciclopirox topical solution, 8% (nail lacquer) should be used only under medica

Соединенные Штаты - английский - NLM (National Library of Medicine)

bausch health us, llc - ciclopirox (unii: 19w019zdrj) (ciclopirox - unii:19w019zdrj) - ciclopirox 10 mg in 0.96 ml - loprox® (ciclopirox) shampoo, 1% is indicated for the topical treatment of seborrheic dermatitis of the scalp in adults. none. teratogenic effects: pregnancy category b there are no adequate or well-controlled studies in pregnant women. therefore, loprox shampoo should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. oral embryofetal developmental studies were conducted in mice, rats, rabbits, and monkeys. ciclopirox or ciclopirox olamine was orally administered during the period of organogenesis. no maternal toxicity, embryotoxicity or teratogenicity were noted at the highest doses of 77, 125, 80, and 38.5 mg/kg/day ciclopirox in mice, rats, rabbits, and monkeys, respectively (approximately 13, 42, 54, and 26 times the maximum recommended human dose based on body surface area comparisons, respectively). dermal embryofetal developmental studies were conducted in rats and rabbits with ciclopirox olamine dissolved in peg 400. ciclopirox olamine was topically adm

Соединенные Штаты - английский - NLM (National Library of Medicine)

e. fougera & co. a division of fougera pharmaceuticals inc. - ciclopirox (unii: 19w019zdrj) (ciclopirox - unii:19w019zdrj) - none. teratogenic effects: pregnancy category b there are no adequate or well-controlled studies in pregnant women. therefore, ciclopirox shampoo should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. oral embryofetal developmental studies were conducted in mice, rats, rabbits and monkeys. ciclopirox or ciclopirox olamine was orally administered during the period of organogenesis. no maternal toxicity, embryotoxicity or teratogenicity were noted at the highest doses of 77, 125, 80 and 38.5 mg/kg/day ciclopirox in mice, rats, rabbits and monkeys, respectively (approximately 13, 42, 54 and 26 times the maximum recommended human dose based on body surface area comparisons, respectively). dermal embryofetal developmental studies were conducted in rats and rabbits with ciclopirox olamine dissolved in peg 400. ciclopirox olamine was topically administered during the period of organogenesis. no maternal toxicity, embryotoxicity or teratogenicity were noted at the hig

Соединенные Штаты - английский - NLM (National Library of Medicine)

teligent pharma, inc. - ciclopirox (unii: 19w019zdrj) (ciclopirox - unii:19w019zdrj) - none. teratogenic effects: pregnancy category b there are no adequate or well-controlled studies in pregnant women. therefore, ciclopirox shampoo should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. oral embryofetal developmental studies were conducted in mice, rats, rabbits and monkeys. ciclopirox or ciclopirox olamine was orally administered during the period of organogenesis. no maternal toxicity, embryotoxicity or teratogenicity were noted at the highest doses of 77, 125, 80 and 38.5 mg/kg/day ciclopirox in mice, rats, rabbits and monkeys, respectively (approximately 13, 42, 54 and 26 times the maximum recommended human dose based on body surface area comparisons, respectively). dermal embryofetal developmental studies were conducted in rats and rabbits with ciclopirox olamine dissolved in peg 400. ciclopirox olamine was topically administered during the period of organogenesis. no maternal toxicity, embryotoxicity or teratogenicity were noted at the hig

Соединенные Штаты - английский - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - ciclopirox (unii: 19w019zdrj) (ciclopirox - unii:19w019zdrj) - ciclopirox 80 mg in 1 ml - (to understand fully the indication for this product, please read the entire indications and usage section of the labeling.) ciclopirox topical solution, 8% as a component of a comprehensive management program, is indicated as topical treatment in immunocompetent patients with mild to moderate onychomycosis of fingernails and toenails without lunula involvement, due to trichophyton rubrum . the comprehensive management program includes removal of the unattached, infected nails as frequently as monthly, by a health care professional who has special competence in the diagnosis and treatment of nail disorders, including minor nail procedures. - no studies have been conducted to determine whether ciclopirox might reduce the effectiveness of systemic antifungal agents for onychomycosis. therefore, the concomitant use of 8% ciclopirox topical solution and systemic antifungal agents for onychomycosis, is not recommended. - ciclopirox topical solution, 8% should be used only under medical